PItt-Ohio State-Georgetown Clinical Trials Unit

皮特-俄亥俄州立-乔治敦临床试验中心

• 批准号: 8609805
• 负责人: SUSAN L KOLETAR
• 金额: $ 410.29万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8609805
• 关键词: AIDS clinical trial group; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Administrative Efficiency; Affect; Anti-Retroviral Agents; Antimicrobial Resistance; Appalachian Region; Area; Bacteria; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Communities; Comorbidity; Development; Disease; District of Columbia; Drug Interactions; Enrollment; Ensure; Epidemic; Goals; Grant; HIV; HIV Vaccine Trials Network; HIV prevention trials network; HIV therapy; HIV vaccine; Hepatitis; Hepatitis C; Immunology; Inflammation; Laboratories; Leadership; Mentors; Microbicide Trials Network; Monitor; Morbidity - disease rate; Ohio; Oral; Organ; Participant; Pennsylvania; Performance; Population; Populations at Risk; Prevention strategy; Prophylactic treatment; Protocols documentation; Recruitment Activity; Research; Research Personnel; Safety; Scientific Advances and Accomplishments; Site; Therapy Clinical Trials; Tuberculosis; Universities; Vaginal Ring; Viral; West Virginia; Work; clinical research site; follow-up; meetings; member; microbicide; mortality; rectal microbicide; research study; virology

DESCRIPTION (provided by applicant): The OSUPITTGU Clinical Trials Unit (CTU), composed of 3 Clinical Research Sites (CRSs) at the University of Pittsburgh (PITT CRS) in Pittsburgh, PA, Ohio State University (OSU CRS) in Columbus, Ohio, and Georgetown University (GU CRS) in Washington, DC, proposes to continue its productive affiliations with the AIDS Clinical Trials Group (ACTG) and the Microbicide Trials Network (MTN), contributing scientific and administrative leadership, as well as enrollment and follow-up of participants in a broad range of studies conducted by both Networks. Additionally, the OSUPITTGU CTU is poised to continue its participation as protocol specific sites for studies in the HIV Prevention Trials Network (HPTN) and the HIV Vaccine Trials Network (HVTN), and has capacity to expand further in terms of scientific capabilities and access to both affected and at risk populations. As such, the OSUPITTGU CTU will contribute to the research agendas of several DAIDS HIV/AIDS Clinical Trials Networks and thereby achieve the desired efficiency for a CTU. The Aims of this application are: 1) to advance the scientific agenda of the ACTG through development and implementation of high-priority research studies focused on HIV Reservoirs and Viral Eradication (HIV Cure), Hepatitis, and End-organ Disease and Inflammation; 2) to advance the scientific agenda of the MTN through development and implementation of high-priority research studies on the safety and efficacy of antiretroviral-containing vaginal rings, rectal microbicides, and combination approaches; 3) to rapidly expand existing CTU capacity into new areas of HIV and antimicrobial resistance research to meet the evolving needs of DAIDS- and DMID-sponsored Networks; 4) to provide access to DAIDS-sponsored trials for hard-to-reach and impoverished populations most impacted by the HIV/AIDS epidemic in western PA, central OH, northern Appalachia, and Washington, DC, where no other access to therapeutic trials exists; 5) to recruit, enroll, retain and monitor study participants in high-priority protocols of the ACTG, MTN, HPTN, and HVTN, and meet or exceed performance standards for these Networks; 6) to partner with affected communities and community advisory boards at each CRS throughout these endeavors; and 7) to mentor promising young investigators at each CRS to become skilled researchers. The collective expertise, administrative efficiency, and performance record of the OSUPITTGU CTU over the last grant cycle ensure that these Aims are achievable and that the CTU will make important contributions to the research agendas of DAIDS and DMID Networks.

描述（由申请人提供）：OSUPITTGU 临床试验单位 (CTU)，由 3 个临床研究中心 (CRS) 组成，分别位于宾夕法尼亚州匹兹堡的匹兹堡大学 (PITT CRS) 和俄亥俄州哥伦布的俄亥俄州立大学 (OSU CRS)和华盛顿特区的乔治城大学 (GU CRS) 提议继续与艾滋病临床试验小组 (ACTG) 和杀菌剂试验网络 (MTN)，在两个网络进行的广泛研究中提供科学和行政领导，以及参与者的登记和随访。此外，OSUPITTGU CTU 准备继续作为 HIV 预防试验网络 (HPTN) 和 HIV 疫苗试验网络 (HVTN) 的研究方案特定站点，并有能力进一步扩大科学能力和获取受影响人群和高危人群。因此，OSUPITTGU CTU 将为多个 DAIDS HIV/AIDS 临床试验网络的研究议程做出贡献，从而实现 CTU 所需的效率。本申请的目的是： 1) 通过开发和实施重点关注 HIV 病毒库和病毒根除（HIV 治愈）、肝炎以及终末器官疾病和炎症的高优先级研究来推进 ACTG 的科学议程； 2) 通过开发和实施关于含抗逆转录病毒的阴道环、直肠杀菌剂和组合方法的安全性和有效性的高优先级研究，推进 MTN 的科学议程； 3) 迅速将现有 CTU 能力扩展到艾滋病毒和抗菌药物耐药性研究的新领域，以满足 DAIDS 和 DMID 赞助网络不断变化的需求； 4) 为宾夕法尼亚州西部、俄亥俄州中部、阿巴拉契亚北部和华盛顿特区受艾滋病毒/艾滋病流行影响最严重的难以接触和贫困人口提供 DAIDS 赞助的试验，这些地区没有其他治疗试验的机会; 5) 招募、入组、保留和监控 ACTG、MTN、HPTN 和 HVTN 高优先级方案的研究参与者，并达到或超过这些网络的绩效标准； 6) 在整个这些努力中与受影响社区和每个 CRS 的社区咨询委员会合作； 7) 指导每个 CRS 有前途的年轻研究人员成为熟练的研究人员。 OSUPITTGU CTU 在上一个资助周期的集体专业知识、管理效率和绩效记录确保了这些目标是可以实现的，并且 CTU 将为 DAIDS 和 DMID 网络的研究议程做出重要贡献。